Clinical trial · Interventional
Open-Label Extension of Other SZ1839 (Iressa) Trials
Multi-Centre, Open-Label Extension Trial of Treatment With ZD1839 (Iressa) in Patients Who Have Been Treated in Other ZD1839 Clinical Trials and May Benefit From Continued Monotherapy ZD 1839.
NCT00635973CI-TRIAL-00002230completedPhase 3ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
A trial to assess patients who have been treated with Iressa in a previous clinical trial and may benefit from continued treatment with Iressa.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cancer | Malignant Neoplasm | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Gefitinib (Iressa) | Drug | Gefitinib | ALIAS |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Adverse Events
- timeFrame
- Every 28 days
Secondary outcomes (2)
- measure
- Progression Free Survival
- timeFrame
- Every 28 days
- measure
- Survival
- timeFrame
- Every 28 days
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Received treatment in a previous Iressa clinical trial * Provided Informed Consent to participate in the trial * 30 days or less since completing the previous Iressa trial. Exclusion Criteria: * Radiotherapy completed more than 14 days before starting treatment in this trial * Incomplete healing from prior surgery * Withdrawal from previous Iressa trial due to unacceptable toxicity to major organs
References
Publications (0)
Data not yet available
No reference posted for this study.